辛伐他汀对哮喘模型大鼠血清IL-4、IFN-γ水平影响的实验研究

Objective To study the impact of simvastatin on the asthma model rats serum interleukin-4(IL-4) and interferon-γ(IFN-γ) level changes,which provide the experimental basis for simvastatin treatment of bronchial asthma.Methods 32 male SD rats were randomly divided into four groups:normal control group,asthmatic model group,the dexamethasone treatment group and the simvastatin group,with 8 rats in each group,using ovalbumin (OVA) sensitization and aerosol inhalation to stimulate the rat model of asthma.Double sites sandwich enzyme-linked immunosorbent assay in serum IL-4 and IFN-γ levels.Results The levels of serum IFN-γ were significantly lower than the normal control group,IL-4 content was significantly higher than the normal control group,has a very significant difference (P ＜0.01),respectively (83.71±8.89) ng/L and (106.62± 13.33) ng/L;IFN-γ in serum compared with asthmatic model group,simvastatin groupand dexamethasone group were (95.93 ±11.74)ng/L and (96.34 ± 11.64) ng/L,significantly higher than the asthma model group,a significant difference (P ＜0.05),and no significant difference (P ＞ 0.05) between the two treatment groups;compared with asthmatic model group,IL-4 levels in both treatment groups were significantly lower (P ＜0.01) of IL-4 levels were (79.08 ± 7.34) ng/L and (73.39 ± 7.76) ng/L in no significant difference between therapy groups (P ＞ 0.05).Conclusions Simvastatin and dexam-ethasone can significantly improve the level of serum IFN-γ in asthmatic rats,reducing the level of serum IL-4 had better control of asthma.